New biosensors quickly detect coronavirus proteins and antibodies
(University of Washington Health Sciences/UW Medicine) Researchers have designed protein-based biosensors that glow when mixed with targeted molecules, such as components of the pandemic coronavirus or specific COVID-19 antibodies. This development could allow for faster, more widespread testing in the near future. Similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker for some breast cancers) and Bcl-2 (which has clinical significance in some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news

Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
TOKYO& MUNICH& BASKING RIDGE, N.J.--(BUSINESS WIRE) January 15, 2021 -- Daiichi Sankyo Company, Ltd.  (hereafter, Daiichi Sankyo) and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 15, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
The histone deacetylase inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor –positive, HER2-negative, advanced breast cancer in a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - January 11, 2021 Category: Pharmaceuticals Source Type: news

Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer
Basel, 11 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient. The image analysis algorithms use artificial intelligence to support pathologists in making faster, more accurate patient diagnoses in breast cancer. (Source: Roche Media News)
Source: Roche Media News - January 11, 2021 Category: Pharmaceuticals Source Type: news

Margetuximab for HER2+ Metastatic Breast Cancer Falls Short Margetuximab for HER2+ Metastatic Breast Cancer Falls Short
With such a small improvement in progression-free survival, margetuximab is ' simply not enough ' for advanced HER2+ breast cancer, says Dr Kathy Miller.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 7, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Advances in HER2+ MBC From SABCS 2020 Advances in HER2+ MBC From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2+ metastatic breast cancer, including gains in progression-free survival in patients with brain metastases.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Highlights in Metastatic Breast Cancer From SABCS 2020 Highlights in Metastatic Breast Cancer From SABCS 2020
From SABCS 2020, Dr Harold Burstein reports on advances for patients with HER2- metastatic breast cancer, including updates on immunotherapy and promising results for a novel oral taxane.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the ti...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news

Margetuximab Approved for HER2+ Metastatic Breast Cancer Margetuximab Approved for HER2+ Metastatic Breast Cancer
A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Margenza (margetuximab-cmkb) for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
ROCKVILLE, MD, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 16, 2020 Category: Drugs & Pharmacology Source Type: news

Effect of BMI on Treatment Response in HER2 Breast Cancer Effect of BMI on Treatment Response in HER2 Breast Cancer
Is there an association between obesity and treatment response? A study examined the potential impacts of BMI among breast cancer patients receiving neo-adjuvant anti-HER2 therapies.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

What Does It Mean to Have HER2-Positive Breast Cancer?
HER2, short for human epidermal growth factor receptor 2, describes a protein that plays a role in normal breast cell development. But in some breast cancers, the HER2 gene produces too many proteins. (Source: WebMD Health)
Source: WebMD Health - December 14, 2020 Category: Consumer Health News Source Type: news